Acadia Pharmaceuticals' Rebranding and AI Integration
Acadia Pharmaceuticals' CEO, Catherine Owen Adams, discusses the company's recent rebranding, expansion into rare disease marketing, and the role of AI in its marketing strategy.
Adams spoke with MM+M about the rebranding, the benefits and challenges of marketing as a smaller biotech, and how her marketing background is influencing the company's direction into 2026.
The company is using AI throughout commercialization and marketing as part of its new brand identity.
- Expansion into rare disease marketing
- Integration of AI in marketing strategy
- Challenges and benefits of marketing as a smaller biotech
Author's summary: Acadia Pharmaceuticals rebrands and expands into rare disease marketing with AI integration.